A few days ago, the International Iberian Nanotechnology Laboratory (INL) and University of Minho (UMinho) signed a licensing agreement with IPLEXMED, a spin-out company specializing in advanced medical diagnostics. The agreement grants the company rights to commercialize a new graphene-based diagnostic platform.
The technology, developed under the MULTIMAL project and patented in 2024 with the support of HORIZON 2020, utilizes monolayer graphene field-effect transistor (FET) sensors. These sensors are functionalized for the non-invasive, rapid, and highly sensitive detection of malaria and other diseases, delivering attomolar-level performance from saliva or urine samples.
According to INL leadership, this milestone marks the transition of graphene sensor technology from the research bench to commercially available solutions, exemplifying real-world impact for advanced materials.
